Imatinib Mesylate News and Research

RSS
Imatinib mesylate (also called Gleevec® or STI571) is approved by the U.S. Food and Drug Administration (FDA) for the treatment of some forms of adult and pediatric chronic myelogenous leukemia (CML), and for the treatment of a rare form of cancer called gastrointestinal stromal tumor (GIST).

With CML, imatinib works by blocking an abnormal enzyme characteristic of the disease. In GIST, imatinib blocks a different abnormal enzyme found on the tumor cells.

Imatinib is the first approved drug to directly turn off the signal of a protein known to cause a cancer. Other molecular-targeting drugs previously approved by the FDA interfere with proteins associated with other cancers, but not with proteins that directly cause the disease.

Imatinib is being investigated for its effectiveness against other kinds of cancer, as well, including acute lymphocytic leukemia and hypereosinophilic syndrome (HES).
Unregulated pharmacy benefit manager practices may contribute to escalating expenses

Unregulated pharmacy benefit manager practices may contribute to escalating expenses

Adding chemotherapy to treatment regimen can give children with PVS a chance to grow up

Adding chemotherapy to treatment regimen can give children with PVS a chance to grow up

Bayer-new phase 3 liver cancer data

Bayer-new phase 3 liver cancer data

Drug similar to Gleevec may help tame some brain cancers

Drug similar to Gleevec may help tame some brain cancers

Bayer enrolls patients for Phase III trial of Stivarga (regorafenib) tablets in colorectal cancer

Bayer enrolls patients for Phase III trial of Stivarga (regorafenib) tablets in colorectal cancer

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

European Commission approves Stivarga tablets for treatment of patients with mCRC

European Commission approves Stivarga tablets for treatment of patients with mCRC

Scientists discover molecular pathway that can prevent death of oocytes due to chemotherapy

Scientists discover molecular pathway that can prevent death of oocytes due to chemotherapy

Bayer HealthCare to present new data on oncology portfolio at ASCO meeting

Bayer HealthCare to present new data on oncology portfolio at ASCO meeting

Bayer HealthCare: Patient enrollment underway in Phase III trial of Stivarga tablets for treatment of HCC

Bayer HealthCare: Patient enrollment underway in Phase III trial of Stivarga tablets for treatment of HCC

A*STAR's professor receives Szent-Gy-rgyi prize for groundbreaking cancer pill

A*STAR's professor receives Szent-Gy-rgyi prize for groundbreaking cancer pill

India's Supreme Court rules against Novartis AG in 'landmark' patent case

India's Supreme Court rules against Novartis AG in 'landmark' patent case

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Imatinib mesylate effectively treats children with neurofibromatosis type 1 tumors

Imatinib mesylate effectively treats children with neurofibromatosis type 1 tumors

EMA CHMP adopts positive opinion for Pfizer’s axitinib to treat advanced renal cell carcinoma

EMA CHMP adopts positive opinion for Pfizer’s axitinib to treat advanced renal cell carcinoma

Pfizer fails to meet primary endpoint in TORISEL Phase 3 study for advanced RCC

Pfizer fails to meet primary endpoint in TORISEL Phase 3 study for advanced RCC

FDA extends Novartis' Gleevec label to three-year treatment in patients with KIT+ GIST after surgery

FDA extends Novartis' Gleevec label to three-year treatment in patients with KIT+ GIST after surgery

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

New data from Pfizer's investigational oncology compounds to be presented at EMCC 2011

New data from Pfizer's investigational oncology compounds to be presented at EMCC 2011

Health Canada approves Tasigna for newly diagnosed Philadelphia chromosome-positive CML

Health Canada approves Tasigna for newly diagnosed Philadelphia chromosome-positive CML